Table 1.
Pre-conditioning strategies to strengthen adipose-derived stem cell (ASC) function.
| Priming Regimen | In Vitro Effects | In Vivo Effects | Model/Condition | Reference |
|---|---|---|---|---|
| IFN-γ | IDO ↑ T-cell suppression ↑ |
- | - | [80] |
| IFN-γ | PD-L1 ↑ COX-2/PGE2 ↑ PBMC proliferation ↓ |
- | - | [81] |
| IFN-γ | IDO ↑ |
T-cell infiltration ↓ Treg induction ↑ |
Obliterative bronchiolitis model | [82] |
| TNF-α | Proliferation ↑ Mobilization ↑ Osteogenesis ↑ |
- | - | [83] |
| TNF-α | IL-6 secretion ↑ IL-8 secretion ↑ |
EP cell homing ↑ Angiogenesis ↑ |
Ischemic hind limb model | [84] |
| IFN-γ/ TNF-α | PGE2 ↑ IL-10 ↑ CCL2 ↑ |
- | - | [85] |
| IFN-γ/ TNF-α IL-17 | iNOS ↑ | T-cell suppression ↑ | ConA-induced hepatitis model | [88] |
| IFN-γ/ TNF-α/ IL-6 | IDO ↑ Proliferation ↓ Cell diameter ↑ PBMC proliferation ↓ |
- | - | [89] |
| IL-1β/ IL-6/ IL-23 | No morphologic change CD45 expression ↑ Differentiation ↑ Allogeneic T-cell proliferation ↓ TGF-β ↑, IL-4 ↓ |
- | - | [90] |
| TGF-β | CXCR4 ↑ | Cancer homing ↑ Tumor volume ↓ Prolonged survival time ↑ |
Glioblastoma | [91] |
| LPS | IL-6, TNF-α, HGF ↑ VEGF ↑ |
Liver regeneration ↑ Serum AST, ALT ↓ |
Partial hepatectomy model | [101] |
| PolyI:C | PGE2 ↑ IDO activity ↑ Restoring ASC inhibitory effect on pre-stimulated T cells |
- | - | [102] |
↑; upregulated or enhanced, ↓; downregulated or reduced, -; not applicable.